Clinical Trials Logo

Lenvatinib clinical trials

View clinical trials related to Lenvatinib.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06070636 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with infiltrative hepatocellular carcinoma.

NCT ID: NCT06061276 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with intermediate-advanced huge hepatocellular carcinoma.

NCT ID: NCT05286320 Not yet recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Start date: March 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

HCC patients with PVTT (main trunk or the first-degree branch) treated with the combination of pembrolizumab (Ketruda), lenvatinib (Lenvima), and SBRT.